⚕ GalenOps CRO console
← SITE010 (ESP)

SITE010-0449

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE010 (ESP) (Dr. Silva) · consented 2023-09-16
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-01-19 (study day 115); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-03-12 (study day 168); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-05-04 (study day 221); relationship: N

mild assessed 2026-08-18

Grade 1 Nausea — outcome: UNKNOWN; onset 2024-09-21 (study day 361); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-10-03 (study day 373); relationship: Y; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-10-25 (study day 395); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-11-23 (study day 424); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-12-13 (study day 444); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.